Strat Aero PLC's (AERO) "Under Review" Rating Reaffirmed at Beaufort Securities
- Author: Joanne Flowers Feb 16, 2017,
Feb 16, 2017, 16:49
This would imply the analyst believes there is now a potential upside of 31.8% from today's opening price of 925.5 GBX.
J P Morgan Chase & Co reaffirmed their neutral rating on shares of Gemfields PLC (LON:GEM) in a research report report published on Monday morning.
Several other research firms have also recently weighed in on BOO. Investec lifted their price objective on Boohoo.Com PLC from GBX 150 ($1.87) to GBX 155 ($1.94) and gave the company a buy rating in a research report on Tuesday, January 10th. BNP Paribas upgraded HSBC Holdings plc to an "outperform" rating and set a GBX 750 ($9.37) target price on the stock in a report on Thursday, January 19th. Numis Securities Ltd restated a buy rating and issued a GBX 85 ($1.06) price target on shares of Gemfields PLC in a research report on Friday, December 2nd. Four investment analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company.
Strat Aero PLC (LON:AERO) opened at 0.10 on Wednesday. The 1 year high for the stock price is 1032.19 GBX while the 52 week low is 640.22 GBX. Four analysts rating the company a strong buy, seven analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of 300.09GBX. The company's market capitalization is GBX 1.05 billion. The 50 day moving average of LON:BRBY is 1574.84 and the 200 day moving average is 1440.13. The company's stock had a trading volume of 218,750 shares.
This article was posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another site, it was illegally copied and reposted in violation of U.S. & worldwide copyright law. The shares were purchased at an average cost of GBX 674 ($8.42) per share, for a total transaction of £125,903.20 ($157,339.67).
Indivior PLC (Indivior) is a specialty pharmaceutical company.